Merger & Integration Update CONTENTS ARE CONFIDENTIAL John White Vice President  of Business Development 1 Filed by Wright Medical Group, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Wright Medical Group, Inc. Commission File No.: 001-35823

CONTENTS ARE CONFIDENTIAL 2

Transaction Summary Key Transaction Milestones Closing Considerations • Merger Announcement: October 27, 2014 • FTC Second Request: January 28, 2015 • Best Case Close Date: Q2 2015 • Satisfactory resolution of FTC second request o Assume lower extremity product divestitures o Products in question represent ~$14.9 million in U.S. revenue and ~$21 million in global revenue • Customary closing conditions such as Wright and Tornier shareholder approval  CONTENTS ARE CONFIDENTIAL 3

Integration Guiding Principles Motivated Employees Ensure the combined company is a great place to work Satisfied Shareholders Enable growth Delighted Customers Integrate thoughtfully, expediently and efficiently CONTENTS ARE CONFIDENTIAL 4

Certain Areas Require Dedicated  Cross-Functional Planning Cross Functional Process is naturally migrating from functional blueprints to cross functional work plans Migrate from Must Haves to Day 1 Readiness Detailed Plans Planning will progress to the next level of detail; teams will begin to get granular Planning Phases 1 Making Strong Progress to Day 1 and 180+ CONTENTS ARE CONFIDENTIAL 5

Senior Leadership announced on January 29, 2015 CONTENTS ARE CONFIDENTIAL 6

Executive Alignment Culture Assessment and Action Planning Employee Town Halls Week 1 Celebration Events Culture Launch Ongoing Culture Activities Salesforce Presentations Communications and Culture Pre-Day 1 Post-Day 1 Day 1 Leadership Meetings and Information Cascade Press Releases Employee Integration Updates Leadership Announcements Change Management Session “Pulse Survey” Merger Close Press Release Day 1 Guides for Managers, Employees and Sales Day 1 Letters and FAQs to HCP/Customer/Supplier/Partner Website Communications Investor/Media Interviews Direct Calls for Key Customers, HCPs and Partners Customer Roadshows Functional Change Implementations Goals on our Path to Day 1 • Create and deliver cohesive communications to effectively communicate with key stakeholders: shareholders, employees, customers, external constituents • Advance the company’s corporate culture and align on the vision, mission and values for the combined organization • Encourage employee engagement and enable effective workforce transition CONTENTS ARE CONFIDENTIAL 7

IMPORTANT ADDITIONAL INFORMATION ABOUT THIS TRANSACTION AND WHERE TO FIND IT

In connection with the proposed merger, Tornier has filed with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4 that includes a preliminary joint proxy statement of Wright and Tornier that also constitutes a preliminary prospectus of Tornier. The registration statement is not complete and will be further amended. Wright and Tornier will make the final joint proxy statement/prospectus available to their respective shareholders. Investors are urged to read the final joint proxy statement/prospectus when it becomes available, because it will contain important information. The registration statement, definitive joint proxy statement/prospectus and other documents filed by Tornier and Wright with the SEC will be available free of charge at the SEC’s website (www.sec.gov) and from Tornier and Wright. Requests for copies of the joint proxy statement/prospectus and other documents filed by Wright with the SEC may be made by contacting Julie D. Tracy, Senior Vice President and Chief Communications Officer by phone at (901) 290-5817 or by email at julie.tracy@wmt.com, and request for copies of the joint proxy statement/prospectus and other documents filed by Tornier may be made by contacting Shawn McCormick, Chief Financial Officer by phone at (952) 426-7646 or by email at shawn.mccormick@tornier.com.

Wright, Tornier, their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from Wright’s and Tornier’s respective shareholders in connection with the proposed transaction. Information about the directors and executive officers of Wright and their ownership of Wright stock is set forth in Wright’s annual report on Form 10-K for the fiscal year ended December 31, 2014, which was filed with the SEC on February 26, 2015 and its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on March 31, 2014. Information regarding Tornier’s directors and executive officers is contained in Tornier’s annual report on Form 10-K for the fiscal year ended December 28, 2014, which was filed with the SEC on February 24, 2015, and its proxy statement for its 2014 annual general meeting of shareholders, which was filed with the SEC on May 16, 2014. These documents can be obtained free of charge from the sources indicated above. Certain directors, executive officers and employees of Wright and Tornier may have direct or indirect interest in the transaction due to securities holdings, vesting of equity awards and rights to severance payments. Additional information regarding the participants in the solicitation of Wright and Tornier shareholders will be included in the joint proxy statement/prospectus.